News >

Avelumab Falls Short in Phase III Gastric Cancer Trial

Jason M. Broderick @jasoncology
Published: Tuesday, Nov 28, 2017

Chris Boshoff, MD, PhD

Chris Boshoff, MD, PhD
Avelumab (Bavencio) did not improve overall survival (OS) compared with chemotherapy in previously treated patients with gastric or gastroesophageal junction (GEJ) adenocarcinoma, according to findings from the phase III JAVELIN Gastric 300 trial.

Avelumab currently has FDA approved indications for urothelial carcinoma and Merkel cell carcinoma.
Chung HC, Arkenau H-T, Wyrwicz L, et al. Safety, PD-L1 expression, and clinical activity of avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with advanced gastric or gastroesophageal junction cancer. J Clin Oncol. 2016;34 (suppl 4S; abstr 167).

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: How Can We Optimize Outcomes in Head and Neck Cancers with Immunotherapeutic Strategies?Oct 31, 20191.5
The Patient and Provider Connection™: Effective Communication to Optimize the Diagnosis and Management of Irritable Bowel Syndrome and Chronic Idiopathic ConstipationOct 31, 20191.0
Publication Bottom Border
Border Publication